Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 18, 2018 - Issue sup1: Proceedings of the Fifth International Symposium on Thymosins in Health and Disease
Submit an article Journal homepage
2,726
Views
8
CrossRef citations to date
0
Altmetric
Editorial

From thymus to cystic fibrosis: the amazing life of thymosin alpha 1

Enrico GaraciUniversity San Raffaele and IRCCS San Raffaele, Rome, ItalyCorrespondence[email protected]
View further author information
Pages 9-11 | Received 19 Jan 2018, Accepted 31 May 2018, Published online: 31 Jul 2018

References

  • Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593–608.
  • Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232–4239.
  • Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265–2274.
  • Garaci E, Pica F, Matteucci C, et al. Historical review on thymosin alpha1 in oncology: preclinical and clinical experiences. Expert Opin Biol Ther. 2015;15(Suppl 1):S31–9.
  • Tuthill CW, King RS. Thymosin Apha. 1–A peptide immune modulator with a broad range of clinical applications. Clin Exp Pharmacol. 2013;3(4):1000133.
  • Marshall G Jr. Thymosin-induced immunoregulation: clinical potentials for allergy and asthma endotypes. Expert Opin Biol Ther. 2018 Mar;6:1–3.
  • Perruccio K, Bonifazi P, Topini F, et al. Thymosin alpha1 to harness immunity to pathogens after haploidentical hematopoietic transplantation. Ann N Y Acad Sci. 2010;1194:153–161.
  • Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992–2001.
  • Rubin BK. Cystic fibrosis: myths. Mistakes Dogma Paediatr Respir Rev. 2014;15(1):113–116.
  • Rubin BK. Cystic Fibrosis. 2017-the year in review. Respir Care. 2018;63(2):238–4110.
  • Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol Med. 2012;18(2):81–91.
  • Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem. 2008;77:701–726.
  • Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531.
  • Hisert KB, Heltshe SL, Pope C, et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit Care Med. 2017;195(12):1617–1628.
  • Schneider EK, Reyes-Ortega F, Li J, et al. Can cystic fibrosis patients finally catch a breath with lumacaftor/ivacaftor? Clin Pharmacol Ther. 2017;101(1):130–141.
  • Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR. N Engl J Med. 2015;373(18):1783–1784.
  • Galietta LJ. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors. Paediatr Drugs. 2013;15(5):393–402.
  • Zhou Y, Song K, Painter RG, et al. Cystic fibrosis transmembrane conductance regulator recruitment to phagosomes in neutrophils. J Innate Immun. 2013;5(3):219–230.
  • Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol. 2006;8(9):933–944.
  • Hector A, Schäfer H, Pöschel S, et al. Regulatory T-cell impairment in cystic fibrosis patients with chronic pseudomonas infection. Am J Respir Crit Care Med. 2015;191(8):914–923.
  • Iannitti RG, Carvalho A, Cunha C, et al. Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. Am J Respir Crit Care Med. 2013;187(6):609–620.
  • Tiringer K, Treis A, Fucik P, et al. A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2013;187(6):621–629.
  • Romani L, Oikonomou V, Moretti S, et al. Thymosin alpha1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nat Med. 2017;23(5):590–600.
  • Maiuri L, Raia V, Kroemer G. Strategies for the etiological therapy of cystic fibrosis. Cell Death Differ. 2017;24(11):1825–1844.
  • Luciani A, Villella VR, Esposito S, et al. Cystic fibrosis: a disorder with defective autophagy. Autophagy. 2011;7(1):104–106.
  • Tomati V, Caci E, Pesce E, et al. Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia. JCI Insight. 2018;3(3):pii98699.
  • Kota A, Deshpande D, Haghi M, et al. Autophagy and airway fibrosis: is there a link? F1000Res. 2017 Apr;3(6):409.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.